---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-22-000026"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:33:48.895681+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q1 commercial revenue $4.2M, down from $4.8M; reaffirms FY2022 revenue $27-32M

## Summary
- Commercial revenue $4.2M (Q1 2021: $4.8M, including $0.2M BARDA); recurring revenue up 66% to $2.7M.
- Net loss ($14.9M) vs ($22.1M) prior year; EPS ($0.35) reflecting higher share count after IPO.
- Cash and investments $184.2M, no debt; reaffirms FY2022 revenue guidance $27-32M (growth 25-50%).
- Placed 2 systems, completed validation of 9 systems; expects Q2 system placements similar to Q1.
- Beta testing of rapid sterility system with global top 20 pharma expected to begin later in Q2.

## SEC filing metadata
- accession: 0001380106-22-000026
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000026/0001380106-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000026/c106-20220510x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-22-000026
- JSON: https://secwatch.observer/filing/0001380106-22-000026.json
- Plain text: https://secwatch.observer/filing/0001380106-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.